improves the hepatitis B e antigen (HBeAg) seroconversion rate in HBeAg-positive chronic hepatitis B patients. However, baseline factors predicting favourable responses to PEG-IFN-a-2a remain largely unknown. Methods: A total of 115 HBeAg-positive chronic hepatitis B patients who had a pre-therapy serum alanine aminotransferase (ALT) level over two times the upper limit of normal and received PEG-IFN-a-2a for 6-12 months were consecutively enrolled according to the local reimbursed guidelines. HBeAg seroconversion and combined response defined as HBeAg seroconversion, HBV-DNA level <20,000 IU/ml as well as ALT normalization at 6 months off therapy were primary and secondary therapeutic end points, respectively. Baseline viral factors, including viral load, genotype and major sequences of precore stop codon/ basal core promoter (BCP), and host factors, including three single nucleotide polymorphisms among the HLA-DPA1, HLA-DPB1 and IL28B regions, were determined to correlate with therapeutic end points. Results: HBeAg seroconversion and combined response rates were 26.1% and 18.3%, respectively. By multivariate analysis, BCP mutation (OR 8.04, 95% CI 2.00-32.28) and rs3077 G/G genotype (OR 3.49, 95% CI 1.12-10.84) were associated with a higher HBeAg seroconversion rate; BCP mutation (OR 9.28, 95% CI 1.92-44.99) and baseline viral load <2×10 6 IU/ml (OR 4.78, 95% CI 1.37-16.69) were associated with a higher combined response rate. Conclusions: BCP mutation is associated with higher HBeAg seroconversion and combined response rates at 6 months off therapy in HBeAg-positive chronic hepatitis B patients treated with PEG-IFN-a-2a. Genetic variants in the HLA-DPA1 region may also affect treatment-induced HBeAg seroconversion.
Introduction
with the baseline serum HBV-DNA level in a doseresponse manner [2, 3] . In order to delay or even prevent the progression of disease, the primary goal of chronic hepatitis B treatment is to permanently suppress HBV replication [4] .
Study of the natural history of HBV infection suggests that hepatitis B e antigen (HBeAg) seroconversion usually reflects a transition from high to low viral replication and confers a favourable clinical outcome [5] . Pegylated interferon (PEG-IFN)-a, one of the approved agents for the treatment of chronic hepatitis B, has been shown to increase the HBeAg seroconversion rate [6] . Although PEG-IFN causes more side effects than nucleoside/nucleotide analogues, it generates a better and more sustained treatment response [6] . In addition, the finite duration of PEG-IFN therapy is also preferred by young chronic hepatitis B patients.
For HBeAg-positive chronic hepatitis B patients with genotype B or genotype C infection, a treatmentresponse predictive model for PEG-IFN-a therapy has been proposed [7] . This model combines a pre-therapy alanine aminotransferase (ALT) level greater than two times the upper limit of normal (ULN) and lower viral load (<2×10 8 IU/ml) to predict a higher response rate [7] . However, the clinical utility of this model is quite limited, since the majority of chronic hepatitis B patients receiving antiviral therapy in Taiwan have already met the criteria for a favourable response [8, 9] . Therefore, it is mandatory to identify other factors predicting a favourable treatment outcome in patients with PEG-IFN-a-based therapy.
Among variations of the HBV genome, emergence of precore (PC) stop codon (G1896A) and basal core promoter (BCP) mutation (A1762T/G1764A) can abolish or reduce the production of HBeAg in in vitro studies [10] . In fact, pre-therapy PC and BCP mutations have been reported to increase the HBeAg clearance rate in patients receiving lamivudine and IFN treatment, respectively [8, 11, 12] . Taking these lines of evidence together, the baseline genetic variations of HBV should be investigated to clarify their effects on the treatment response to PEG-IFN-a.
Recently, research using a genome-wide association approach has disclosed several host genetic variants affecting the natural course or treatment outcome of viral hepatitis. Genetic variations in the interleukin 28B gene (IL28B) have been shown to correlate with PEG-IFN-induced HCV clearance in chronic hepatitis C patients [13] [14] [15] . In addition, two genetic variations of HLA-DPA1 and HLA-DPB1 are associated with HBV clearance in an Asian HBV cohort study [16] . Whether these host single nucleotide polymorphisms (SNP) affect the treatment response to PEG-IFN in chronic hepatitis B patients remains unknown and therefore deserves further study. Ren-Ai Branch and 11 (9.6%) from Cathay General Hospital. All of them were positive for hepatitis B surface antigen and HBeAg for more than 6 months. None of them had evidence suggestive of other viral hepatitis, autoimmune liver disease or inheritable disorders such as haemochromatosis or Wilson's disease, or had a history of alcoholism. All of them had no evidence of hepatic decompensation (serum total bilirubin level >2 mg/dl or prothrombin time prolongation for >3 s).
Methods

Patients
Patients were tested for serum HBeAg, antibody to HBeAg (anti-HBe), ALT, and serum bilirubin level at baseline, 3 months and 6 months of therapy, and 3 months and 6 months off therapy. The baseline serum samples were tested for HBV viral load, genotype, PC and BCP sequences. Serum samples at 6 months off therapy were tested for HBV viral load. All serum samples were stored at -20°C until use.
In Taiwan, the Bureau of National Health Insurance launched a reimbursement programme for the treatment of chronic hepatitis B since October 2003. According to the recommendation of the Asian-Pacific consensus statement on the management of chronic hepatitis B [17] , HBeAg-positive chronic hepatitis B patients with pre-therapy serum ALT levels over two times the ULN were eligible to receive PEG-IFN-a-2a for 6 months. Therefore, most of our patients received PEG-IFN-a-2a for 6 months and only eight patients received PEG-IFN-a-2a for 12 months.
Every enrolled patient signed the informed consent approved by the ethical committee for both blood sampling and genetic testing in each participating centre.
Definitions of treatment responses
The primary therapeutic end point was HBeAg seroconversion at the sixth month of follow-up. The secondary end point was combined response, including HBeAg seroconversion, serum HBV DNA<20,000 IU/ml and normalized ALT level at the sixth month post therapy. Both end points were adopted from prior clinical trials and current treatment guidelines [6, 18] .
Serological assay
Serum hepatitis B surface antigen, HBeAg, anti-HBe and anti-HCV were tested by commercially available kits (Abbott Laboratories, North Chicago, IL, USA).
Quantification of HBV DNA and HBV genotyping
HBV viral load and genotype were determined using the real-time PCR-based single-tube assay as previously described [19] . The dynamic range of HBV-DNA level under this method is from 20 to 2×10 10 IU/ml (100-10 11 copies/ml).
Sequences of the PC and BCP regions of HBV
The PC and BCP regions were directly sequenced as previously described [20] . Briefly, the PC and BCP regions were first amplified by nested-PCR assays. The PCR products were then directly sequenced with an automatic ABI DNA sequencer (Model 377A; Applied Biosystems, Foster City, CA, USA) to determine the nucleotide sequences, with emphasis on nucleotides 1896, 1762 and 1764. The major sequence was determined by the highest signal on the nucleotides in which we are interested.
Determination of single nucleotide polymorphisms of rs3077, rs9277535 and rs8099917
Genomic DNA was extracted from peripheral blood mononuclear cells using the QIAamp kits (Qiagen, Inc., Valencia, CA, USA). Genotyping was performed using the ABI TaqMan allelic discrimination kit and the ABI7900HT Sequence Detection System (Applied Biosystems). Three SNPs located within or around HLA-DPA1, HLA-DPB1 and IL28B loci (rs3077 for HLA-DPA1, rs9277535 for HLA-DPB1 and rs8099917 for IL28B, respectively) were genotyped in all 115 patients.
Statistical analyses
The mean and standard deviation were calculated for continuous variables. The percentage was used for categorical variables. The baseline HBV-DNA level was designed as a categorical variable. Data were analysed by c 2 test, Fisher's exact test and Student's t-test, where appropriate. Multivariable-adjusted OR and 95% CI values were derived for each factor using logistic regression. All of the tests of significance were two-tailed, and P<0.05 was considered statistically significant. Data were collected in a Microsoft Excel database (Microsoft Excel 2001; Microsoft Corporation, Seattle, WA, USA) and analysed with Stata statistical software (version 9.2; Stata Corp., College Station, TX, USA).
Regarding the SNPs, a Hardy-Weinberg disequilibrium test was performed for each SNP [21] . Linkage disequilibrium (LD) index (Lewontin's D′ and r 2 ) calculation was performed by Haploview version 4.1 software [22] . The OR of each haplotype was derived by UNPHASED statistical software version 3.1.4 [23] . Since rs3077 and rs9277535 are within the HLA-DP region on chromosome 6 and 21,839 base pairs apart and rs8099917 is on chromosome 19, LD index calculation and haplotype analysis were performed only for rs3077 and rs9277535.
Results
Baseline characteristics
The demographic data of the 115 HBeAg-positive chronic hepatitis B patients are shown in Table 1 . A total of 18 (15.7%) patients had received lamivudine before but at least 1 year apart. None of them had received standard IFN before. The mean logarithmic value of the pre-therapy viral load was 6.5 ±1.5 IU/ml and it was categorized into high and low viral load by 2×10
6 IU/ml, as recently suggested [24] . The pairwise disequilibrium measure of rs3077 and rs9277535 showed that the two SNPs were in high LD (D′= 0.76 and r 2 = 0.45). In addition, we also compared the viral and host characteristics between genotype B and genotype C patients. Most factors were comparable except that genotype C patients were older, had a higher prevalence of BCP mutation and a lower prevalence of baseline HBV-DNA level ≥2×10
6 IU/ml than genotype B patients ( Figure 1 ).
Baseline factors associated with treatment responses
At 6 months off PEG-IFN-a-2a therapy, the overall HBeAg loss, HBeAg seroconversion and combined response rates were 30.4%, 26.1% and 18.3%, respectively. A total of two patients (1.7%) developed hepatitis B surface antigen seroclearance at 6 months post therapy, and nine patients (7.8%) received oral nucleoside/nucleotide analogues (lamivudine in three patients and entecavir in six patients) during the follow-up period due to hepatitis flares. All of them remained HBeAg-positive at the sixth month of follow-up, and were thus regarded as treatment failures. In the remaining 106 patients, the mean logarithmic value of HBV viral load at 6 months off therapy was 4.86 ±2.22 IU/ml. Regarding the primary end point, all baseline factors but BCP and rs3077 status were comparable between two groups ( 
Primary and secondary end points stratified by combining baseline factors
We further examined factors associated with primary and secondary end points by combining baseline variables, which showed significant difference in univariate and multivariate analyses. BCP status and rs3077 genotype were adopted for the primary end point; BCP status and viral load were adopted for the secondary end point (Figure 2 ). For the primary end point, the positive predictive value was 53.6% and 9.7% for patients with and without combining the rs3077 G/G genotype and BCP mutation (A1762T/G1764A; P<0.001), respectively. For the secondary end point, the positive predictive value was 34.8% and 7.3% for patients with and without low viral load (<2×10 6 IU/ml) and BCP mutation (A1762T/G1764A; P=0.002), respectively.
Discussion
An investigation of factors that predict treatment response in HBeAg-positive patients receiving PEG-IFN therapy is clinically important. A prior meta-analysis study shows that genotype A, a lower serum HBV-DNA level (<2×10 8 IU/ml) and a higher ALT level (>2 times the ULN) correlate with a better treatment response [7] . In this study, which enrolled only patients with ALT more than two times the ULN and genotype B or genotype C infection, we found that BCP mutation (A1762T/ G1764A) was the only factor independently associated with a higher HBeAg seroconversion and combined response rates. In addition, the rs3077 G/G genotype was associated with a higher HBeAg seroconversion rate. Other factors such as a lower HBV-DNA level Mean, log IU/ml (±sd) 6.5 (±1.5) Median, log IU/ml (range) 6.9 (2.7-8.9) rs8099917 G/G, n (%) 1 (0.9) G/T, n (%) 11 (9.6) T/T, n (%) 103 (89.6) rs3077 A/A, n (%) 6 (5. (<2×10 6 IU/ml), genotype B and higher ALT level (>5 times the ULN) were associated with a higher combined response rate. These findings suggest that a subgroup of chronic hepatitis B patients with BCP mutation and rs3077 G/G genotype can achieve the rate of PEG-IFNinduced HBeAg seroconversion up to 53.6%.
In this study, our results showed that patients with baseline BCP mutation (A1762T/G1764A) had an increased HBeAg seroconversion and combined response rates at 6 months off therapy. Similar observations have been found in HBeAg-positive patients receiving interferon-based therapy [11, 12] . These lines of evidence suggest that viral strains of BCP mutation are more susceptible to IFN-based therapy in HBeAgpositive patients. Both in vivo and in vitro studies also demonstrated that the dinucleotide mutations (A1762T/G1764A) in the HBV genome lead to the reduction of HBeAg production by suppressing HBV precore messenger RNA transcription [25] [26] [27] [28] [29] [30] . This unique characteristic of BCP mutation may partly explain its tendency to lose HBeAg spontaneously or under immune modulatory treatment. However, whether this observation could be extrapolated to oral nucleoside/nucleotide analogues remains unknown and needs further investigation [8] .
In addition to BCP mutation, a tendency for patients with HBV genotype B infection towards a better response rate (OR 3.77; P=0.08 for the primary end point, and OR 5.74; P=0.042 for the secondary end point) seemed interesting and worthy of discussion. First, the statistical significance appeared only in multivariate analysis, but not in univariate analysis. This inconsistent result may be attributed to the high prevalence of BCP mutation and lower viral load in patients with genotype C infection, which may counteract the unfavourable effect of genotype C on the treatment response. Second, previous studies using 6-month standard IFN treatment already demonstrated the therapeutic differences between HBV genotype B and genotype C [31] ; however, the response rate was comparable between these two genotypes in a clinical trial using 12-month PEG-IFN-a-2a therapy [6] . One possibility to explain this discrepancy is that genotype C patients may benefit more from 12-month PEG-IFN therapy than genotype B patients, so the influence of HBV genotype on treatment response is masked by prolonging the treatment duration [32] . Unfortunately, our current data were unable to answer this interesting and important question because only eight patients received 12 months of treatment. Prospective clinical trials with the study design of categorizing treatment duration by HBV genotypes would clarify the issue.
In this study, other factors such as lower HBV-DNA level (<2×10 6 IU/ml) and higher ALT level (>5 times the ULN) were associated with a higher combined response High viral load is ≥2x10 6 IU/ml. a P<0.05. ALT, alanine aminotransferase; BCP mutation, basal core promoter mutation (A1762T/G1764A); PC mutation, precore stop codon mutation (G1896A); ULN, upper limit of normal. rate but not HBeAg seroconversion rate. Although statistically not significant, multivariate analysis showed that lower HBV-DNA levels and higher ALT levels tended to be associated with HBeAg seroconversion (P=0.126 and P=0.080, respectively). These results may be due to the relatively small patient numbers. Further large studies are needed to examine this important issue.
Few studies have investigated whether host genetic factors affect the response to IFN-based therapy in HBeAg-positive patients [33, 34] . In this study, we first focused on SNPs associated with HBV clearance. In a recent study using the genome-wide association study approach, the 'A' alleles of rs3077 (in HLA-DPA1 region) and rs9277535 (in HLA-DPB1 region) are found to protect against HBV persistence in Asians [16] . We thus hypothesized that chronic hepatitis B patients with 'A' alleles of rs3077 and rs9277535 could have a higher HBeAg seroconversion rate to PEG-IFN therapy. Although frequencies of SNPs at HLA regions might vary significantly across populations, the effect of these two SNPs has been replicated in both Japanese and Thai people, providing the rationale to investigate the clinical significance of these two SNPs in Taiwanese patients. Contrary to the hypothesis, our data showed that the GA and GG haplotypes of rs3077-rs9277535 were associated with a higher HBeAg seroconversion rate compared with the AA haplotype. This discrepancy could be reasoned by the following speculations. First, Table 2 . Comparisons between responders and non-responders to PEG-IFN-a-2a at 6 months off therapy Values are n (%) unless otherwise indicated.
a Major sequence. b Only 114 patients were analysed due to genotyping failure of one sample. Combined response: hepatitis B e antigen (HBeAg) seroconversion, serum HBV-DNA level <20,000 IU/ml and normalized alanine aminotransferase (ALT) at 6 months off therapy. PEG-IFN, pegylated interferon; ULN, upper limit of normal. because these two SNPs might be surrogates of given classical HLA alleles, the possibility cannot be excluded that patients with HLA alleles prone to clear the virus may respond worse to IFN therapy. Second, these SNPs might not be the perfect surrogates of classical HLA loci implicated in a previous study [16] , because the LD between classical HLA loci and nearby SNPs might be different across different populations. To prove or disprove these speculations, we need to clarify the relationship between these SNPs and linked HLA loci as well as understand what the risk or benefit of certain HLA loci is. Although more evidence is required, these findings suggest that genetic variations in the HLA-DP region may still play a key role in spontaneous or treatmentinduced HBV clearance. We also investigated the effect of a given SNP in IL28B. From in vitro studies, IL28B has been shown to suppress HBV and HCV replication [35] . Several IL28B-associated SNPs, including rs12979860 and rs8099917, are documented to affect treatment response to PEG-IFN-based therapy in chronic hepatitis C patients [13] [14] [15] . In this study, only rs8099917 was assayed because its effect on HCV treatment was discovered in Asian chronic hepatitis C patients. In addition, the high LD between rs12979860 and rs8099917 has been reported in two separate studies (r 2 ≈0.5) [13, 15] . However, the effect of rs8099917 was not replicated in chronic hepatitis B patients receiving PEG-IFN, suggesting different mechanisms of PEG-IFN-induced virus clearance exist between HBV and HCV infection.
This study had few limitations. First, most of our patients received 6 months of PEG-IFN-a-2a. The treatment duration is mainly based on the recommendation of the Asian-Pacific treatment guidelines [17] . Therefore, whether our findings could be extrapolated to chronic hepatitis B patients receiving a longer duration of PEG-IFN awaits further study. Second, HBV population is usually composed of a mixture of closely related viral genomes [36] . Since we analysed only major PC and BCP sequences of the HBV genome by direct sequencing, the influence of minor viral strain was not evaluated in this study. Although limitations existed in this study, our study provided clinically useful clues to predicting a better response in PEG-IFN-treated HBeAg-positive patients, especially in areas endemic for HBV genotype B and genotype C infection.
In conclusion, HBV BCP mutation (A1762T/ G1764A) is associated with higher HBeAg seroconversion and combined response rates at 6 months off therapy in HBeAg-positive chronic hepatitis B patients treated with PEG-IFN-a-2a. Host factors such as genetic variations in HLA-DPA1 region may also affect treatment-induced HBeAg seroconversion. 
